Biotech Revival: Big Pharma Bets on Innovation and Acquisitions

Just a few years ago, biotech seemed to have lost its luster on the stock market. Rising interest rates, more difficult financing conditions, and numerous setbacks in clinical trials caused many companies to lose significant value.

But while many investors have recently focused on artificial intelligence or the GLP-1 success story, another trend has been developing in the background: Major pharmaceutical companies are once again investing billions in innovative biotechnologies. For many market observers, this is a signal that the next wave of acquisitions may have already begun. Companies like Mesoblast could thus come back into sharper focus.

Big Pharma needs to find new growth drivers

The pressure on major pharmaceutical companies is mounting. Numerous high-revenue drugs will lose their patent protection in the coming years, while at the same time, the demands on innovation and productivity are increasing. Accordingly, industry giants are investing heavily in new technologies. Eli Lilly is continuously expanding its pipeline. In addition to its multi-billion-dollar successes in the obesity and diabetes markets, the company is investing heavily in oncology and immunology and recently announced the acquisition of blood cancer specialist Ajax Therapeutics.

GSK is also continuing its expansion. With the announced acquisition of Nuvalent for approximately US$10.6 billion, the pharmaceutical company is securing several promising oncology programs in advanced stages of development. The message is clear: Innovative platforms are once again highly valued. Even Novo Nordisk, whose current success is primarily based on GLP-1 drugs, is investing heavily in expanding its research platforms and production capacities. At the same time, the company is working to diversify its pipeline beyond diabetes and obesity.

Acquisitions in the biotech sector are often cheaper than in-house research

This development is hardly surprising. Developing a new drug often takes more than ten years and consumes billions of dollars. At the same time, the risk of clinical setbacks remains high. For many pharmaceutical companies, it has therefore become more economically attractive to acquire already well-developed technologies or entire companies.

Instead of bearing all the development risks themselves, they buy access to validated platforms, experienced research teams, and advanced clinical programs. This exact pattern was already observed in previous waves of innovation – from monoclonal antibodies to mRNA to CAR-T cell therapies.

Cell therapy is evolving far beyond cancer

The market for cell therapies is currently developing particularly dynamically. While CAR-T therapies were initially used exclusively for certain blood cancers, attention is now turning to significantly broader indications. Studies are underway worldwide on autoimmune diseases, chronic inflammation, cardiovascular diseases, and regenerative medicine.

At the same time, new production methods and automated manufacturing processes are improving the economic prospects of the entire industry. This is creating markets for Big Pharma that could extend far beyond traditional oncology.

Mesoblast pursues its own approach

Mesoblast positions itself precisely in this environment. Unlike many CAR-T cell therapy companies, the Australian biotechnology firm focuses on allogeneic mesenchymal flow cells (MSCs). These are derived from healthy donors and can be produced using standardized methods. This is intended to make manufacturing, storage, and subsequent application significantly easier to scale than with many patient-specific cell therapies.

With Ryoncil, Mesoblast already has an FDA-approved cell therapy for the treatment of steroid-refractory acute graft-versus-host disease in children. Simultaneously, the company is developing further programs for chronic back pain, heart failure, and inflammatory diseases. This combination of existing commercialization and several advanced development projects is what sets Mesoblast apart from numerous smaller biotech companies that are still entirely in clinical development.

The valuation discount could open up opportunities

Many biotech companies are valued significantly lower today than during the biotech boom of a few years ago. At the same time, large pharmaceutical companies have substantial liquidity and are under pressure to renew their product pipelines early.

Historically, major waves of acquisitions have often occurred precisely during such market phases: valuations were moderate, while the industry’s need for innovation increased. Of course, biotechnology remains a high-risk sector. Clinical trials, regulatory decisions, and the commercial success of new therapies are unpredictable. Nevertheless, many investors are closely monitoring which companies already possess validated technologies and initial commercial structures.

Conclusion

The multi-billion dollar investments by Novo Nordisk, Eli Lilly, and GSK demonstrate that the pharmaceutical industry is already considering its next growth phase. While GLP-1 drugs are transforming the diabetes and obesity markets and new oncology programs are achieving billion-dollar valuations, innovative cell therapies are increasingly becoming the focus of strategic investments.

For investors, therefore, the question of which drug will be the next success is not the only one that could be of interest. Equally compelling is the question of which platform technologies will become acquisition targets in the future. With an already approved cell therapy, a scalable MSC platform, and several clinical development programs, Mesoblast operates precisely in a market segment that is gaining increasing strategic importance for major pharmaceutical companies.

__

(Featured image by Marek Studzinski via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in FinanzNachrichten.de. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.